3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
Open Access
- 1 October 2005
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 16, viii36-viii38
- https://doi.org/10.1093/annonc/mdi965
Abstract
1NCIC-CTG (Canada); 2NSGO (Scandinavia); 3AGO-OVAR (Germany); 4GOG (USA); 5ANZGOG (Australia–New Zealand); 6EORTC (Europe); 7GEICO (Spain); 8JGOG (Japan); 9GINECO (France); 10MRC/NCRI (UK); 11SGCTG (Scotland, UK); 12RTOG (USA); 13NCI-USKeywords
This publication has 4 references indexed in Scilit:
- Carcinoma of the ovaryInternational Journal of Gynecology & Obstetrics, 2003
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996